Jeffrey C. Gildersleeve, Ph.D.
Jeffrey C. Gildersleeve, Ph.D.
Senior Investigator
Head, Chemical Glycobiology Section

The Gildersleeve group works at the interface of chemistry, glycobiology, and immunology. We use chemical approaches to 1) aid the design and development of cancer and HIV vaccines, 2) identify clinically useful biomarkers, and 3) better understand the roles of carbohydrates in cancer and HIV immunology. To facilitate these studies, we have developed a glycan microarray that allows high-throughput profiling of serum anti-glycan antibody populations.

Link to additional information about Dr. Gildersleeve's research.

Areas of Expertise
1) glycan array technology, 2) cancer biomarkers, 3) cancer vaccines, 4) synthesis of carbohydrate antigens

Contact Info

Jeffrey C. Gildersleeve, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 376, Room 208
Frederick, MD 21702-1201
301-846-5699
gildersj@mail.nih.gov

​The Gildersleeve group works at the interface of chemistry, glycobiology, and immunology. We use chemical approaches to 1) aid the design and development of cancer and HIV vaccines, 2) identify clinically useful biomarkers, and 3) better understand the roles of carbohydrates in cancer and HIV immunology. To facilitate these studies, we have developed a glycan microarray that allows high-throughput profiling of serum anti-glycan antibody populations. A number of other groups have also developed glycan arrays; our array is unique in that we use multivalent neoglycoproteins as our array components. This format allows us to readily translate array results to other applications and affords novel approaches to vary glycan presentation.

The main focus of our current and future research is to study the roles of anti-glycan antibodies in the development, progression, and treatment of cancer. These projects are shedding new light on how cancer vaccines work and are uncovering new biomarkers for the early detection, diagnosis, and prognosis of cancer. In particular, we are studying immune responses induced by PROSTVAC-VF, a cancer vaccine in Phase III clinical trials for the treatment of advanced prostate cancer. In addition, we are identifying biomarkers for the early detection and prognosis of ovarian and lung cancer. These projects are highly collaborative in nature and are focused on translating basic research from the bench to the clinic. We rely heavily on glycan array technology to study immune responses to carbohydrates, and we continually strive to improve this technology. First, carbohydrate-protein interactions often involve formation of multivalent complexes. Therefore, presentation is a key feature of recognition. We have developed several new approaches to vary carbohydrate presentation on the surface of the array, including methods to vary glycan density and neoglycoprotein density. Second, we use synthetic organic chemistry to obtain a diverse set of tumor-associated carbohydrates and glycopeptides to populate our array.

Collaborations and Carbohydrate Microarray Screening. We are frequently asked to screen lectins, antibodies, and other entities on our array. Although we are not a core facility and do not provide screening services per se, we are happy to collaborate on many projects. Please contact Jeff Gildersleeve for more details.

Scientific Focus Areas:
Chemical Biology, Immunology
  1. Zhang Y, Li Q, Rodriguez LG, Gildersleeve JC.
    J Am Chem Soc. 132(28): 9653-62, 2010. [ Journal Article ]
  2. Yin Z, Comellas-Aragones M, Chowdhury S, Bentley P, Kaczanowska K, Benmohamed L, Gildersleeve JC, Finn MG, Huang X.
    ACS Chem Biol. 8: 1253-62, 2013. [ Journal Article ]
  3. Park S, Gildersleeve JC, Blixt O, Shin I.
    Chem Soc Rev. 42: 4310-26, 2013. [ Journal Article ]
  4. Zhang Y, Muthana SM, Farnsworth D, Ludek O, Adams K, Barchi JJ, Gildersleeve JC.
    J Am Chem Soc. 134: 6316-25, 2012. [ Journal Article ]
  5. Campbell CT, Llewellyn SR, Damberg T, Morgan IL, Robert-Guroff M, Gildersleeve JC.
    PLoS ONE. 8: e75302, 2013. [ Journal Article ]

Jeff Gildersleeve obtained his B.S. degree in biology in 1993 from the University of California at San Diego. He obtained his Ph.D. degree in organic chemistry at Princeton University under the guidance of Professor Dan Kahne, and completed postdoctoral training with Professor Peter Schultz at The Scripps Research Institute. In the summer of 2003, he began his current position as a Principal Investigator in the Chemical Biology Laboratory (formerly the Laboratory of Medicinal Chemistry). The Gildersleeve group uses chemical approaches and glycan microarray technology to study the roles of anti-carbohydrate immune responses in the development, progression, and treatment of cancer and HIV. Dr. Gildersleeve is a recipient of the 2006 NCI Director's Innovation Award and the 2011 David Y. Gin New Investigator Award from the Division of Carbohydrate Chemistry of the American Chemical Society.

Position Number of Positions Contact E-mail Contact Name Contact Phone
Postdoctoral Fellow 1

gildersj@mail.nih.gov

Jeff Gildersleeve 301-846-5699
Name Position
David Farnsworth M.S. Research Chemist
Ruslan Gibadullin Summer Student
Saddam Muthana Ph.D. Postdoctoral Fellow (CRTA)
Eric Sterner Ph.D. Postdoctoral Fellow (CRTA)
W. Wright Postbaccalaureate Fellow
Li Xia Ph.D. Postdoctoral Fellow (Visiting)

Research

​The Gildersleeve group works at the interface of chemistry, glycobiology, and immunology. We use chemical approaches to 1) aid the design and development of cancer and HIV vaccines, 2) identify clinically useful biomarkers, and 3) better understand the roles of carbohydrates in cancer and HIV immunology. To facilitate these studies, we have developed a glycan microarray that allows high-throughput profiling of serum anti-glycan antibody populations. A number of other groups have also developed glycan arrays; our array is unique in that we use multivalent neoglycoproteins as our array components. This format allows us to readily translate array results to other applications and affords novel approaches to vary glycan presentation.

The main focus of our current and future research is to study the roles of anti-glycan antibodies in the development, progression, and treatment of cancer. These projects are shedding new light on how cancer vaccines work and are uncovering new biomarkers for the early detection, diagnosis, and prognosis of cancer. In particular, we are studying immune responses induced by PROSTVAC-VF, a cancer vaccine in Phase III clinical trials for the treatment of advanced prostate cancer. In addition, we are identifying biomarkers for the early detection and prognosis of ovarian and lung cancer. These projects are highly collaborative in nature and are focused on translating basic research from the bench to the clinic. We rely heavily on glycan array technology to study immune responses to carbohydrates, and we continually strive to improve this technology. First, carbohydrate-protein interactions often involve formation of multivalent complexes. Therefore, presentation is a key feature of recognition. We have developed several new approaches to vary carbohydrate presentation on the surface of the array, including methods to vary glycan density and neoglycoprotein density. Second, we use synthetic organic chemistry to obtain a diverse set of tumor-associated carbohydrates and glycopeptides to populate our array.

Collaborations and Carbohydrate Microarray Screening. We are frequently asked to screen lectins, antibodies, and other entities on our array. Although we are not a core facility and do not provide screening services per se, we are happy to collaborate on many projects. Please contact Jeff Gildersleeve for more details.

Scientific Focus Areas:
Chemical Biology, Immunology

Publications

  1. Zhang Y, Li Q, Rodriguez LG, Gildersleeve JC.
    J Am Chem Soc. 132(28): 9653-62, 2010. [ Journal Article ]
  2. Yin Z, Comellas-Aragones M, Chowdhury S, Bentley P, Kaczanowska K, Benmohamed L, Gildersleeve JC, Finn MG, Huang X.
    ACS Chem Biol. 8: 1253-62, 2013. [ Journal Article ]
  3. Park S, Gildersleeve JC, Blixt O, Shin I.
    Chem Soc Rev. 42: 4310-26, 2013. [ Journal Article ]
  4. Zhang Y, Muthana SM, Farnsworth D, Ludek O, Adams K, Barchi JJ, Gildersleeve JC.
    J Am Chem Soc. 134: 6316-25, 2012. [ Journal Article ]
  5. Campbell CT, Llewellyn SR, Damberg T, Morgan IL, Robert-Guroff M, Gildersleeve JC.
    PLoS ONE. 8: e75302, 2013. [ Journal Article ]

Biography

Jeff Gildersleeve obtained his B.S. degree in biology in 1993 from the University of California at San Diego. He obtained his Ph.D. degree in organic chemistry at Princeton University under the guidance of Professor Dan Kahne, and completed postdoctoral training with Professor Peter Schultz at The Scripps Research Institute. In the summer of 2003, he began his current position as a Principal Investigator in the Chemical Biology Laboratory (formerly the Laboratory of Medicinal Chemistry). The Gildersleeve group uses chemical approaches and glycan microarray technology to study the roles of anti-carbohydrate immune responses in the development, progression, and treatment of cancer and HIV. Dr. Gildersleeve is a recipient of the 2006 NCI Director's Innovation Award and the 2011 David Y. Gin New Investigator Award from the Division of Carbohydrate Chemistry of the American Chemical Society.

Positions

Position Number of Positions Contact E-mail Contact Name Contact Phone
Postdoctoral Fellow 1

gildersj@mail.nih.gov

Jeff Gildersleeve 301-846-5699

Team

Name Position
David Farnsworth M.S. Research Chemist
Ruslan Gibadullin Summer Student
Saddam Muthana Ph.D. Postdoctoral Fellow (CRTA)
Eric Sterner Ph.D. Postdoctoral Fellow (CRTA)
W. Wright Postbaccalaureate Fellow
Li Xia Ph.D. Postdoctoral Fellow (Visiting)